


Personalized Stem Cells Announces First Patient in Brazilian COVID-19 Clinical Trial Licensed to Sorrento Therapeutics

Personalized Stem Cells announces first patient enrolled in Phase 2 Brazilian COVID-19 stem cell clinical trial licensed to Sorrento Therapeutics.

POWAY, CALIFORNIA, US, September 21, 2021 /EINPresswire.com/ -- [Personalized Stem Cells, Inc](#) (PSC), an adipose-derived stem cell company, announces the first patient has been enrolled in a Brazilian Phase 2 COVID-19 stem cell clinical trial. The trial, which is being conducted by Sorrento



Therapeutics (Nasdaq: SRNE, "Sorrento"), is a randomized, placebo-controlled study designed to evaluate the safety and efficacy of three allogeneic (donor-derived) mesenchymal stem cell infusions administered on varying schedules in 100 patients suffering from acute respiratory distress syndrome (ARDS) as a result of COVID-19 infection.

The initial Phase 1b trial was conducted in California at UCSF Fresno. In the initial study, ten patients that were hospitalized and required oxygen supplementation, were all discharged from the hospital shortly after completing treatment with stem cells. These promising results helped secure approval for the Phase 2 study in Brazil. Additionally, Sorrento plans to begin enrollment for two more Phase 2 COVID-19 stem cell studies including a parallel Phase 2 placebo-controlled safety study to be conducted across multiple sites in the United States and a pulmonary long-hauler Phase 2 safety and efficacy study across multiple sites in Brazil.

FDA approval for the Phase 1b clinical trial conducted in the United States was secured by PSC in July 2020. PSC, which primarily focuses on orthopedics, went on to grant global rights to its adipose derived allogeneic mesenchymal stem cell (MSC) program, including the COVID-19 therapy candidate, to Sorrento Therapeutics in October 2020.

As discussed in a peer-reviewed scientific article published by PSC and collaborating scientists on the [rationale behind using stem cells to treat COVID-19](#), MSCs have demonstrated the capacity to

inhibit lung damage, reduce inflammation, dampen immune responses and aid with alveolar fluid clearance. Additionally, MSCs produce molecules that are antimicrobial and reduce pain. Recently, the application of MSCs in the context of ongoing COVID-19 disease and other viral respiratory illnesses has demonstrated reduced patient mortality and, in some cases, improved long-term pulmonary function.

[About Personalized Stem Cells, Inc.](#)

Personalized Stem Cells was formed in 2018 to advance human regenerative medicine by securing FDA approval for autologous stem cells for serious diseases with limited treatment options. This privately held biopharmaceutical enterprise, based near San Diego (California), is conducting clinical trials and developing stem cell products in the areas of orthopedics, pain, and traumatic brain injury. PSC has licensed a portfolio of patents and applications in the field of regenerative medicine which includes patent applications covering treatment of lung diseases including COVID-19.

Kristi Hauta, Marketing
Personalized Stem Cells, Inc
+1 833-772-3557
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/551881039>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.